GULZAR BALICH: Open Payments
NPI 1962026054 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,192 in 42 payments from 11 companies in 2025. Trend: 2023 $732 · 2024 $1,609 · 2025 $1,192
Food & beverage: $1,192
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 15 | $381 |
| AstraZeneca Pharmaceuticals LP | 7 | $249 |
| Merck Sharp & Dohme LLC | 6 | $130 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $125 |
| Novartis Pharmaceuticals Corporation | 5 | $112 |
| Amgen Inc. | 3 | $54 |
| PFIZER INC. | 1 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| BridgeBio Pharma, Inc. | 1 | $26 |
| Biogen, Inc. | 1 | $22 |
Products named: Kerendia, WAINUA, VERQUVO, JARDIANCE, LEQVIO, REPATHA, ELIQUIS, AMVUTTRA.
Industry payments across NY — which companies pay providers there.
